← Back to Search

PD-1 Inhibitor

TATE + Pembrolizumab for Lung Cancer

Verified Trial
Phase 2
Recruiting
Research Sponsored by Teclison Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Have you been diagnosed with non-small cell lung cancer?
Has your lung cancer spread to your liver?
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 months
Awards & highlights
No Placebo-Only Group
Approved for 10 Other Conditions

Summary

This trial is testing a new cancer treatment involving Trans-arterial Tirapazamine Embolization (a minimally-invasive procedure) and Pembrolizumab (a cancer immunotherapy drug). The trial is for patients with metastatic non-small cell lung cancer that has spread to the liver, and who have not responded to other treatments.

Who is the study for?
This trial is for adults with metastatic non-small cell lung cancer (NSCLC) who have already tried PD-1/PD-L1 inhibitors and chemotherapy. Patients whose disease has worsened after treatment are eligible to participate.
What is being tested?
The study tests whether combining Tirapazamine with embolization could enhance anti-tumor immunity and make Pembrolizumab effective in lung cancer patients who have failed prior immunotherapy.
What are the potential side effects?
Possible side effects include immune-related reactions due to Pembrolizumab like rash or colitis, liver issues from TATE, fatigue, skin changes, and increased risk of infections.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall Response Rate (ORR)
Secondary study objectives
Duration of Response
PFS
Response rate
+1 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Approved for 10 Other Conditions
This treatment demonstrated efficacy for 10 other conditions.

Trial Design

1Treatment groups
Experimental Treatment
Group I: NSCLCExperimental Treatment1 Intervention
Liver metastatic NSCLC progressed on immune checkpoint inhibitors and chemotherapy

Find a Location

Who is running the clinical trial?

Teclison Ltd.Lead Sponsor
3 Previous Clinical Trials
213 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
4,015 Previous Clinical Trials
5,186,223 Total Patients Enrolled
Ray LeeStudy DirectorTeclison Limited

Media Library

Pembrolizumab (PD-1 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04701476 — Phase 2
Lung Cancer Research Study Groups: NSCLC
Lung Cancer Clinical Trial 2023: Pembrolizumab Highlights & Side Effects. Trial Name: NCT04701476 — Phase 2
Pembrolizumab (PD-1 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04701476 — Phase 2
~23 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top